The Prevalence of antimicrobial resistance in *Staphylococcus aureus* and coagulase-negative Staphylococci strains isolated from inpatients

Parva Farmehr

Shiraz University of Medical Sciences

Javad fathi

Shiraz University of Medical Sciences

Mahtab Hadadi

Shiraz University of Medical Sciences

mohammad motamedifar (✉ motamedm@sums.ac.ir)

Shiraz University of Medical Sciences

Research note

Keywords: Methicillin resistance *Staphylococcus aureus* (MRSA), Methicillin resistance coagulase negative staphylococci (MRCoNS), Nosocomial infection and Antibiotic resistance

Posted Date: May 3rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-24115/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objectives Globally nosocomial infection is a significant problem. Methicillin resistance *Staphylococcus aureus* (MRSA) and Methicillin resistance coagulase negative staphylococci (MRCoNS) are major causes of nosocomial infections. Aim of this study was to determine the prevalence and antimicrobial susceptibility of MRSA and MRCoNS in the southwest of Iran. This cross-sectional study was conducted on 221 non-duplicated staphylococci isolates collected from teaching hospital in Shiraz. The prevalence of MRSA and MRCoNS in clinical samples was identified with conventional microbiological tests. After identification, all of the isolates were subjected to antimicrobial susceptibility test and PCR to identify the presence of *femA*, *mecA* and *pvl* genes.

Result 168 (76%) *S. aureus* and 53 (24%) CoNS were detected. 70 (41.7%) MRSA among 168 *S. aureus*, and 26 (15.48%) MRCoNS among 53 CoNS were examined. Chloramphenicol (65%) and Gentamicin (23%) were the most active antibacterial agents against MRSA and MRCoNS, whereas these isolates were susceptible to SXT (100%). The frequency of *pvl* gene among *S. aureus* strains was 3.57%. There is need for developing the antibiotic policy and limiting the use of powerful antibiotics.

Introduction

Staphylococcus aureus is a remarkably successful pathogen in the healthcare and community setting(1). It is capable of persistence as a pathogen, because of its frequent resistance to multiple antimicrobial agents and its virulence determinants such as enzymes and toxins (2). In recent decades, methicillin resistant *S. aureus* (MRSA) has been a major agent of health care- and community-associated infections manifesting from minor skin diseases to life-threatening infections in many countries (3). Coagulase-negative staphylococci (CoNS) are part of the human normal flora; especially, the skin is also associated with severe infections such as bacteremia and septicemia, particularly in patients with indwelling devices or immunocompromised patients (4). CoNSs consist of a variety of *Staphylococcus* spp. and are usually resistant to most β -lactams antibiotics including methicillin (5). Methicillin-resistant CoNS (MRCoNS) is growing worldwide and has a major role in clinical infections (6). The main mechanism of resistance to methicillin in staphylococci is the expression of *mecA* gene coding penicillin binding protein 2a (PBP2a), a transpeptidase with low affinity for β -lactams which confers resistance to methicillin and other β -lactam antibiotics in staphylococci harboring the gene (8). *mecA* is carried on a mobile genetic element called the Staphylococcal Chromosome Cassette *mec* (SCC*mec*) (9). So far, 12 SCC*mec* types described that HA-MRSA strains carry SCC*mec* types I, II and III, while CA-MRSA strains have SCC*mec* types IV and V (10). In recent years, treatment of MRSA has been one of the major problems in hospitals because these bacteria are multiply resistant and are susceptible only to glycopeptide antibiotics such as vancomycin and investigational drugs (11). Panton-Valentine Leukocidin (PVL or *lukS/F*) is a bi-component pore-forming toxin causing tissue necrosis and lysis of phagocytic leukocytes that is associated with deep-seated abscess, multiple lesions and multiple antibiotic resistances (12). PVL presents in the majority of community associated MRSA isolates and rarely presents in hospital isolates (13). Epidemiological data suggest that high virulence of community-acquired MRSA is associated with

PVL genes (14). Both endemic and epidemic MRSA infections occur globally as infected and colonized patients in hospitals (15). In our hospitals, the incidence rate of MRSA has been increased in clinical isolates and the prevalence of MRCoNs is also rising. Although many studies have been done on prevalence and antibiotic susceptibility of *Staphylococcus*, many of these studies have focused only on MRSA, not on MRCoNS which are similarly important. Therefore, this study aimed to determine the prevalence and antimicrobial susceptibility of MRSA and MRCoNS in teaching hospital in the southwest of Iran.

Methods

Study design and identification of the isolates

This cross-sectional study was performed from March 2016 to March 2017 in Nemazee teaching hospitals in Shiraz. A total of 221 isolates were collected from different clinical specimens such as the blood, urine, stool and sputum with initial diagnosis of *S. aureus*. Bacterial isolates were identified by Gram stain, colony characteristics and conventional biochemical tests, namely catalase and coagulase (slide and tube) reaction; growth on mannitol salt agar and *S. aureus* ATCC 25923 was used as susceptibility control strains for this study.

Antibiotic susceptibility testing

Disk diffusion method (Kirby-bauer) was performed for MRSA and MRCoNS isolates against Gentamicin (10µg), Clindamycin (2µg), Ciprofloxacin (5µg), Erythromycin (15µg), Tetracycline (30µg), Chloramphenicol (30µg), Trimethoprim-sulfamethoxazole (1.25/23.75µg), and Tobramycin (10µg), according to the CLSI guideline (16). Methicillin resistance for *Staphylococcus* spp. isolates was primarily detected based on resistance to cefoxitin (30 µg) disk (Rosco, Denmark) by CLSI recommended disk diffusion method; also, zone diameter ≤ 21 mm was estimated cefoxitin resistant(16).

DNA extraction and polymerase chain reaction (PCR) assay

Whole DNAs of methicillin resistance staphylococci were extracted, using boiling method and used as PCR templates. Detection of the presence of the *mecA*, *femA* and *pvl* genes was confirmed by PCR assay with specific primers (13, 17). PCR amplifications were performed on a T100™ thermal cycler (Bio- Rad, Hercules, CA, USA). The cycling condition was set up as follows: initial denaturation at 96 °C for 3 min; followed by 35 cycles of 30 s at 96°C, annealing for 1 min at 55°C and 2 min at 72°C; and an extension for 10 min at 72°C. PCR products were loaded into the wells of agarose gel (1.5%) carefully and electrophoresed at 75 V for 90 min. Staining was performed with safe stain load dye (CinnaGen Co., Iran) and then observed under the UV trans-illuminator.

Statistical analysis

Statistical analyses of the parameters were conducted using SPSS for Windows statistical software (version 22).

Results

221 staphylococci clinical isolates containing 168 (76%) *S. aureus* and 53 (24%) CoNS were included in the study. Among 221 isolates of staphylococci, 96 (43.4%) methicillin-resistant isolates consisting of 70 (31.7 %) MRSA and 26 (11.8%) MRCoNS were examined. Among 221 isolates, 99 (44.8%) and 122 (55.2%) were from male and female patients, respectively. Among MRCoNS isolates, the frequency of *S. epidermidis* and *S. saprophyticus* was 76.9% and 23.1%, respectively. Also, in both male and female patients, the frequency of *S. epidermidis* (75.5%) was more than *S. saprophyticus* (15.24). the isolates were collected from different wards of hospitals; MRSA and MRCoNS were isolated more commonly from internal 19 (27.1%) and clinical treatment 10 (38.5%) wards. The frequency of MRSA and MRCoNS in different wards is shown in Table 1.

Table 1: Frequency of MRSA and MRCoNS isolates in different parts of the hospital

MRCoNS No.(%)	MRSA No.(%)	Ward
4(15.4)	18(25.7)	ICU
5(19.2)	10(14.3)	Surgery
2(7.7)	8(11.4)	Acute treatment
3(11.5)	5(7.1)	Pediatric internal
10(38.5)	3(4.3)	Clinical treatment
1(3.8)	7(10)	NICU ^a
1(3.8)	19(27.1)	Internal
26	70	Total

A: Neonatal intensive care unit

The most common sites of bacterial isolation in MRSA and MRCoNS were from bloodstream infections (40%), as presented in Table 2.

Table 2: Frequency of MRSA and MRCoNS isolates based on the isolation site

MRCoNS No. (%)	MRSA No. (%)	Infection source
2	3	Nose
3	10	Wound
1	11	Urine
17	23	Blood
0	5	Spit
0	4	ETT ^a
0	2	Throat
0	2	Auxillary
1	3	Abdominal
0	2	Pleural
1	3	Eye discharge
0	2	Joint
1	0	CSF ^b

A: Endotracheal tube, B: Cerebrospinal fluid

Chloramphenicol (65%) and Gentamicin (23%) were the most active antibacterial agents against MRSA and MRCoNS, whereas these isolates were susceptible to SXT (100%). Intermediate results were also reported as resistant. The antibiotic susceptibility pattern of MRSA and MRCoNS is shown in Table3.

Table3: Pattern of susceptibility and antibiotic resistance in the collected isolates

MRSA		MRCoNS		
S	R	S	R	
24(34.2%)	53(65.7%)	10(38.4%)	16(61.4%)	Tetracycline
5(7.1%)	72(92.8%)	2(7.6%)	22(92.2%)	Chloramphenicol
13(18.5%)	69(81.3%)	5(19.2%)	21(77.6%)	Erythromycin
16(22.8%)	62(77.1%)	6(23%)	20(76.8%)	Tobramycin
10(14.2%)	72(85.6%)	3(11.5%)	23(88.4%)	Gentamicin
0	70(100%)	0	26(100%)	Cefoxitin
36(51.4%)	38(47.5%)	10(38.4%)	16(61.5%)	Clindamycin
20(28.5%)	55(71.3%)	5(19.2%)	21(80.7%)	Ciprofloxacin
70(100%)	0	26(100%)	0	SXT^a

A: Trimethoprim/Sulfamethoxazole

The prevalence of Panton–Valentine Leukocidin (PVL) toxin in the MRSA isolates by detection of *pvl* gene was 6 (3.57%). The PCR results of the confirmatory (*femA* and *mecA*) and the *pvl* genes.

Discussion

Many strains of *Staphylococcus aureus* have been colonized on the surface of humans and animals' bodies, and some of these bacteria are pathogenic (18). The prevalence of MRSA is now increasing worldwide and this bacterium has become a major concern. Different *Staphylococcus* species have the ability to transmit the genes vertically. Today, coagulase-negative staphylococci (CoNS) are among the main human pathogens (19). Horizontal translocation of genes, such as *SCC mec*, occurs easily between MRCoNS and different CoNS strains receiving these genes. Presence of diverse antibiotic resistance genes found in CoNS makes them one of the most important infectious pathogens in the hospital (20, 21). MRCoNS are one of the first causes of bloodstream infections and catheter-related infections that cause high mortality despite antibiotic use and supportive treatments (22). In our study, the rate of CoNS was estimated 53 (24%) in the statistical population of Shiraz teaching hospitals. In a study conducted by Soumya et al. on 173 isolates, 152 (88%) isolates were identified as CoNS(23), whereas in a study in Nepal, about 24% of the isolates were CoNS(24). In a study carried out by Morgenstern et al. in the United States in 2016, they examined the frequency of MRCoNS and MRSA in carriers (through the nose), which estimated the frequency of MRCoNS at 21.4% and the frequency of MRSA isolates at 2%. This study suggests that the high frequency of MRCoNS is possible even in developed communities(25). In our

study, the frequency of MRSA and MRCoNS was evaluated among the patients, showing that the prevalence of MRSA was 31.7% and that of MRCoNS was 11.8%. In comparison to the study performed in the United States, the frequency of MRSA was more. In this study, Cefoxitin disc can be considered as a very effective method for detecting the presence of *mecA* gene although it was found that PCR was an easy, fast and inexpensive method for detecting the presence of this gene. Kim et al. in China used the *16s rRNA* gene PCR to identify different CoNS strains(26) and, as in this study, demonstrated the importance of rapid detection of CoNS. Among the samples examined in this study, 6 (3.57%) had *pvl* gene. The occurrence of *pvl* gene in previous studies has been reported from 2 to 35% (26, 27). In comparison, the obtained results for *pvl* gene in the present study were near the lower limit obtained from similar studies. Chantratita in Thailand estimated this frequency at 16% in hospital patients(27). Kong in Taiwan reported the prevalence of this gene in about 13%(28). Odhiano estimated the prevalence of *pvl* in a hospital in Tehran to be 20%(29). Motamedi reported this prevalence in Ahwaz to be around 3%(30).

In conclusion, the results of the current study showed the prevalence of MRSA and MRCoNS strains resistance against widely used antimicrobial agents. The regular follow-up and continuous monitoring of antibiotic resistance profiles of hospital pathogens, especially staphylococci, will also be useful for selecting an appropriate antibiotic, knowing the changing trends of antibiotic susceptibility pattern, and developing hospital antibiotic policy.

Limitations

The present study had some limitations. First, this was a single-center study; therefore, generalizability of the results to other regions requires further investigations. Second, it was a retrospective study, and the sample size was small. Future studies are suggested to be carried out with a large sample size, and other virulence factors should be evaluated.

Abbreviations

MRSA: methicillin resistant *Staphylococcus aureus*, CoNS: coagulase negative staphylococci; MRCNS: methicillin-resistant coagulase-negative staphylococci; CLSI: Clinical and Laboratory Standards Institute.

Declarations

Authors' contributions

Mohammad Motamedifar Parva Farmehr: conceived the study. Mohammad Motamedifar , Javad Fathi, Mahtab Hadadi: participated in the design of the study and performed the statistical analysis. Javad Fathi, Mahtab Hadadi: interpreted the data. Mohammad Motamedifar: Supervised data collectors. Mohammad Motamedifar Drafting the article or revisiting it critically for important intellectual content. Mohammad Motamedifar Parva Farmehr were project leaders and primary investigators of the study. All authors read and approved the final manuscript.

Author details

1. Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
2. Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Acknowledgments

The authors wish to thank personnel of Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences for his corporation during this investigation.

Competing interests

We declare that we have no conflict of interest.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Consent for publication

There is no limit to the publication.

Ethics approval and consent to participate

This study was in accordance with the declaration of Helsinki and an ethical permission was sought from the institutional Ethics Committee of Shiraz University of Medical Sciences (Approval No. IR.SUMS.REC.1395.S247). However, because we only used leftovers from clinical specimens, the local ethics committee waived the need for informed consent.

Funding

This work was financially supported by Shiraz University of Medical Sciences grant No.10217 and is based on the results of MSc thesis by Parva Farmehr, under the supervision of Prof. M. Motamedifar

References

1. Uhlemann A-C, Otto M, Lowy FD, DeLeo FR. Evolution of community-and healthcare-associated methicillin-resistant *Staphylococcus aureus*. *Infection, genetics and evolution*. 2014;21:563-74.
2. Gill SR, Fouts DE, Archer GL, Mongodin EF, DeBoy RT, Ravel J, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant *Staphylococcus aureus* strain and a biofilm-producing methicillin-resistant *Staphylococcus epidermidis* strain. *Journal of bacteriology*. 2005;187(7):2426-38.

3. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant *Staphylococcus aureus*: an emerging threat. *The Lancet infectious diseases*. 2005;5(5):275-86.
4. Brady MT. Health care-associated infections in the neonatal intensive care unit. *American journal of infection control*. 2005;33(5):268-75.
5. Ghaznavi-Rad E, Fard-Mousavi N, Shahsavari A, Japoni-Nejad A, Van Belkum A. Distribution of staphylococcal cassette chromosome mec types among methicillin-resistant coagulase negative staphylococci in central Iran. *Iranian journal of microbiology*. 2018;10(1):7.
6. Vengust M, Anderson M, Rousseau J, Weese J. Methicillin-resistant staphylococcal colonization in clinically normal dogs and horses in the community. *Letters in applied microbiology*. 2006;43(6):602-6.
7. Peacock JE, Marsik FJ, Wenzel RP. Methicillin-resistant *Staphylococcus aureus*: introduction and spread within a hospital. *Annals of Internal Medicine*. 1980;93(4):526-32.
8. Lim D, Strynadka NC. Structural basis for the β lactam resistance of PBP2a from methicillin-resistant *Staphylococcus aureus*. *Nature Structural & Molecular Biology*. 2002;9(11):870.
9. Daum RS, Ito T, Hiramatsu K, Hussain F, Mongkolrattanothai K, Jamklang M, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant *Staphylococcus aureus* isolates of diverse genetic backgrounds. *The Journal of infectious diseases*. 2002;186(9):1344-7.
10. Mediavilla JR, Chen L, Mathema B, Kreiswirth BN. Global epidemiology of community-associated methicillin resistant *Staphylococcus aureus* (CA-MRSA). *Current opinion in microbiology*. 2012;15(5):588-95.
11. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proceedings of the National Academy of Sciences*. 2002;99(11):7687-92.
12. Graves SF, Kobayashi SD, Braughton KR, Whitney AR, Sturdevant DE, Rasmussen DL, et al. Sublytic concentrations of *Staphylococcus aureus* Panton-Valentine leukocidin alter human PMN gene expression and enhance bactericidal capacity. *Journal of leukocyte biology*. 2012;92(2):361-74.
13. Bhatta DR, Cavaco LM, Nath G, Kumar K, Gaur A, Gokhale S, et al. Association of Panton Valentine Leukocidin (PVL) genes with methicillin resistant *Staphylococcus aureus* (MRSA) in Western Nepal: a matter of concern for community infections (a hospital based prospective study). *BMC infectious diseases*. 2016;16(1):199.
14. Linde H, Wagenlehner F, Strommenger B, Drubel I, Tanzer J, Reischl U, et al. Healthcare-associated outbreaks and community-acquired infections due to MRSA carrying the Panton-Valentine leucocidin gene in southeastern Germany. *European Journal of Clinical Microbiology and Infectious Diseases*. 2005;24(6):419-22.
15. Shinefield HR, Ruff NL. Staphylococcal infections: a historical perspective. *Infectious disease clinics of North America*. 2009;23(1):1-15.
16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 28th Informational Supplement. CLSI document M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

2018.

17. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *Journal of clinical microbiology*. 2000;38(3):1032-5.
18. Yu W, Kim HK, Rauch S, Schneewind O, Missiakas D. Pathogenic conversion of coagulase-negative staphylococci. *Microbes and infection*. 2017;19(2):101-9.
19. Goldstein RR, Kleinfelter L, He X, Micallef SA, George A, Gibbs SG, et al. Higher prevalence of coagulase-negative staphylococci carriage among reclaimed water spray irrigators. *Science of the Total Environment*. 2017;595:35-40.
20. Yang T-Y, Hung W-W, Lin L, Hung W-C, Tseng S-P. *mecA*-related structure in methicillin-resistant coagulase-negative staphylococci from street food in Taiwan. *Scientific reports*. 2017;7:42205.
21. Srednik ME, Tremblay YD, Labrie J, Archambault M, Jacques M, Fernández Cirelli A, et al. Biofilm formation and antimicrobial resistance genes of coagulase-negative staphylococci isolated from cows with mastitis in Argentina. *FEMS microbiology letters*. 2017;364(8):fnx001.
22. Gautam V, Sethuraman N, Kaur R, Sachdev S, Marwaha N, Ray P. Changing epidemiology of coagulase-negative staphylococci in normal flora of skin. *Indian journal of medical microbiology*. 2017;35(2):277.
23. Soumya K, Philip S, Sugathan S, Mathew J, Radhakrishnan E. Virulence factors associated with Coagulase Negative Staphylococci isolated from human infections. *3 Biotech*. 2017;7(2):140.
24. Shrestha LB, Bhattarai NR, Khanal B. Antibiotic resistance and biofilm formation among coagulase-negative staphylococci isolated from clinical samples at a tertiary care hospital of eastern Nepal. *Antimicrobial Resistance & Infection Control*. 2017;6(1):89.
25. Morgenstern M, Erichsen C, Hackl S, Mily J, Militz M, Friederichs J, et al. Antibiotic resistance of commensal *Staphylococcus aureus* and coagulase-negative staphylococci in an international cohort of surgeons: a prospective point-prevalence study. *PLoS One*. 2016;11(2):e0148437.
26. Kim J, Hong J, Lim J-A, Heu S, Roh E. Improved multiplex PCR primers for rapid identification of coagulase-negative staphylococci. *Archives of microbiology*. 2018;200(1):73-83.
27. Chantratita N, Wikraiphat C, Tandhavanant S, Wongsuvan G, Ariyaprasert P, Suntornsut P, et al. Comparison of community-onset *Staphylococcus argenteus* and *Staphylococcus aureus* sepsis in Thailand: a prospective multicentre observational study. *Clinical microbiology and infection*. 2016;22(5):458. e11-. e19.
28. Kang Y-C, Hsiao C-H, Yeh L-K, Ma DH, Chen PY, Lin H-C, et al. Methicillin-resistant staphylococcus aureus ocular infection in Taiwan: Clinical features, Genotyping, and antibiotic susceptibility. *Medicine*. 2015;94(42).
29. Ohadian Moghadam S, Pourmand MR, Mahmoudi M, Sadighian H. Molecular characterization of methicillin-resistant *Staphylococcus aureus*: characterization of major clones and emergence of epidemic clones of sequence type (ST) 36 and ST 121 in Tehran, Iran. *FEMS microbiology letters*. 2015;362(8).

30. Motamedi H, Abadi SSR, Moosavian SM, Torabi M. The association of Pantone-Valentine leukocidin and *mecA* genes in Methicillin-Resistant *Staphylococcus aureus* isolates from patients referred to Educational Hospitals in Ahvaz, Iran. Jundishapur journal of microbiology. 2015;8(8).

Figures

Figure 1

Agarose gel electrophoresis of PCR products for *femA*, *mecA* and *pvl* genes lane 1: DNA ladder, lane 2: negative control sample, lane 3 and 4: *S. aureus* positive isolate containing *femA* gene with 133 bp length and positive control, lanes 5 and 6: *S. aureus* positive isolate containing *mecA* gene with 147 bp length and positive control and lanes 7 and 8: *S. aureus* positive isolate containing *pvlA* gene with 433 bp length and positive control.